Q3 2018 EPS Estimates for Gilead Sciences, Inc. Increased by Leerink Swann (GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) – Investment analysts at Leerink Swann raised their Q3 2018 earnings estimates for Gilead Sciences in a note issued to investors on Monday, October 15th. Leerink Swann analyst G. Porges now forecasts that the biopharmaceutical company will post earnings of $1.60 per share for the quarter, up from their prior forecast of $1.50. Leerink Swann also issued estimates for Gilead Sciences’ Q4 2018 earnings at $1.55 EPS, FY2019 earnings at $5.97 EPS, FY2020 earnings at $6.25 EPS and FY2021 earnings at $6.66 EPS.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.56 by $0.35. The business had revenue of $5.65 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The firm’s revenue for the quarter was down 20.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.56 earnings per share.

A number of other research firms have also recently weighed in on GILD. Wells Fargo & Co upped their target price on shares of Gilead Sciences from $89.00 to $95.00 and gave the company an “outperform” rating in a research note on Thursday, July 26th. Robert W. Baird lowered shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price target on the stock. in a research report on Thursday, July 26th. ValuEngine upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Friday, September 28th. BidaskClub upgraded shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 29th. Finally, Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research report on Monday, October 1st. They issued an “overweight” rating and a $87.00 price target on the stock. Eleven equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $88.24.

NASDAQ GILD opened at $74.17 on Wednesday. The stock has a market capitalization of $100.09 billion, a P/E ratio of 8.66, a price-to-earnings-growth ratio of -3.92 and a beta of 1.01. Gilead Sciences has a twelve month low of $64.27 and a twelve month high of $89.54. The company has a current ratio of 3.00, a quick ratio of 2.92 and a debt-to-equity ratio of 1.23.

Several hedge funds have recently made changes to their positions in the company. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in Gilead Sciences in the second quarter valued at approximately $132,000. Brand Asset Management Group Inc. bought a new stake in Gilead Sciences in the second quarter valued at approximately $139,000. TRUE Private Wealth Advisors bought a new stake in Gilead Sciences in the third quarter valued at approximately $174,000. LFA Lugano Financial Advisors SA increased its stake in Gilead Sciences by 127.0% in the third quarter. LFA Lugano Financial Advisors SA now owns 2,760 shares of the biopharmaceutical company’s stock valued at $213,000 after purchasing an additional 1,544 shares in the last quarter. Finally, Highland Private Wealth Management bought a new stake in Gilead Sciences in the third quarter valued at approximately $219,000. Institutional investors own 77.99% of the company’s stock.

In other news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 4th. The shares were sold at an average price of $74.16, for a total transaction of $3,708,000.00. Following the transaction, the director now directly owns 3,067,762 shares in the company, valued at $227,505,229.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 150,000 shares of company stock worth $11,502,500 over the last quarter. 1.16% of the stock is owned by company insiders.

The business also recently announced a quarterly dividend, which was paid on Thursday, September 27th. Stockholders of record on Friday, September 14th were given a dividend of $0.57 per share. The ex-dividend date was Thursday, September 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 3.07%. Gilead Sciences’s payout ratio is 26.64%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: How is the discount rate different from the Federal Funds rate?

Earnings History and Estimates for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply